Advances in Obesity Treatment: Medication Management for Psychiatrists-View Presentation Slides

View Presentation Slides

Pdf Summary

This document from the American Psychiatric Association discusses advances in obesity treatment, specifically focusing on medication management for psychiatrists. It highlights the significance of obesity, with the prevalence in U.S adults being 42.4% and 21.5% among children. The document emphasizes the importance of psychiatrists in bridging the gap in obesity counseling, noting that fewer than 50% of patients receive weight loss counseling. It outlines the interconnectedness of obesity and psychiatric conditions, such as anxiety, mood disorders, and binge-eating disorder, and discusses strategies for integrating obesity treatment into psychiatric care.<br /><br />The document reviews various pharmacological treatments for obesity, detailing the safety, efficacy, and impact of newly approved medications on psychiatric patients. Medications discussed include metformin, GLP-1 receptor agonists (such as semaglutide and liraglutide), phentermine/topiramate, and orlistat. Considerations for prescription include potential psychiatric adverse effects, contraindications, and the patients' baseline health, with a focus on tailoring treatment to individual needs and condition comorbidities.<br /><br />Psychiatrists are encouraged to collaborate with primary care providers and specialists, considering a multidisciplinary approach to comprehensive care. There are discussions on the need for licensure and training in prescribing obesity medications, ensuring compliance with state guidelines. The document underscores using medication alongside behavioral strategies, such as the 5 A’s framework and motivational interviewing, to optimize patient outcomes. Concluding, it stresses the importance of clear documentation and informed consent when prescribing anti-obesity medications, particularly outside FDA-approved guidelines, and encourages integration of psychiatrists in the holistic treatment of obesity in psychiatric practice.

Keywords

obesity treatment

psychiatric care

medication management

pharmacological treatments

psychiatric conditions

GLP-1 receptor agonists

multidisciplinary approach

behavioral strategies

informed consent

anti-obesity medications